Amr R. Ibrahim, Richard E. Clark, Tessa L. Holyoake, Jenny Byrne, Pat Shepherd, Jane F. Apperley, Dragana Milojkovic, Richard Szydlo, John Goldman, David Marin. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 2011;96(12):1779-1782; https://doi.org/10.3324/haematol.2011.049759.